Sponsor comparison

BioStem Technologies vs Thermo Fisher Scientific

Newsletter sponsorship activity, audience reach, and ad formats — side by side.

BioStem Technologies

biostemtechnologies.com

Thermo Fisher Scientific

thermofisher.com

Sponsorship breakdown

Sponsored by

Last recorded

February 2026

—

Ad copy examples

BioStem Technologies

FROM QUIET COMPOUNDER TO 2026 BREAKOUT? BioStem Technologies (OTCQB: BSEM) is emerging as one of the most compelling small-cap MedTech companies as 2026 begins. The company just completed the acquisition of BioTissue Holdings’ surgical and wound care business, instantly expanding its footprint into hospital-based, acute, and surgical wound care. Zacks Small Cap Research has assigned BSEM a $25.50 price target, highlighting confidence in the company’s profitable growth, clinical validation, and expanding market presence. For context, the stock closed at less than $7 today. Discover why BSEM is setting the standard for profitable, clinically proven MedTech growth in 2026. LEARN MORE

Thermo Fisher Scientific

No ad copy available

Get the full sponsor picture

Contact details, decision makers, email addresses, and complete sponsorship history for both brands.

Start free — no card needed